Latest

After the Mother of All Deals: A Blueprint for the Ireland-India Pharmaceutical Corridor Under the EU-India FTA ◆ The UK-India CETA: A Deep Dive into Bilateral Pharmaceutical Value Chains, API Trade, and Medicine Price Trajectories ◆ Bilateral Breakthrough: How the Historic UK-India Free Trade Agreement Transforms Life Sciences and Key Trade Sectors ◆ Normalization or Correction? Ireland’s Goods Exports Drop 29% in May as Pharma Surplus Narrows ◆ Pilot Photonics Secures €10.4 Million EIC Accelerator Funding to Scale Deeptech Photonic Chips ◆ Intel Announces €5 Billion ($5.7 Billion) AI-Driven Semiconductor Expansion at Leixlip, Kildare ◆ After the Mother of All Deals: A Blueprint for the Ireland-India Pharmaceutical Corridor Under the EU-India FTA ◆ The UK-India CETA: A Deep Dive into Bilateral Pharmaceutical Value Chains, API Trade, and Medicine Price Trajectories ◆ Bilateral Breakthrough: How the Historic UK-India Free Trade Agreement Transforms Life Sciences and Key Trade Sectors ◆ Normalization or Correction? Ireland’s Goods Exports Drop 29% in May as Pharma Surplus Narrows ◆ Pilot Photonics Secures €10.4 Million EIC Accelerator Funding to Scale Deeptech Photonic Chips ◆ Intel Announces €5 Billion ($5.7 Billion) AI-Driven Semiconductor Expansion at Leixlip, Kildare ◆

Search Results

Found 2 results for "luxembourg" across articles, medicines, trials, companies and the glossary

Laprophan Accelerates International Expansion with Completion of Rivopharm Acquisition in Switzerland

Laprophan Accelerates International Expansion with Completion of Rivopharm Acquisition in Switzerland

Moroccan pharmaceutical group Laprophan finalizes its acquisition of a controlling stake in Swiss pharmaceutical firm Rivopharm, securing a strategic industrial base in Europe and expanding its global footprint.

Europe's United Front: How the Beneluxa Initiative is Defending the Pharma Framework Against US Pricing Pressure

Europe's United Front: How the Beneluxa Initiative is Defending the Pharma Framework Against US Pricing Pressure

With the US pushing for individual drug pricing deals and Germany slashing healthcare spending, the Beneluxa Initiative represents five European nations calling for a unified, coordinated approach to protect Europe's pharmaceutical innovation and access to medicines in 2026.